摘要
目的探讨拉米夫定治疗儿童慢性乙型肝炎的临床疗效及安全性。方法将218例慢性乙型肝炎患儿按不同的治疗方法分为拉米夫定组(治疗组)116例和对照组102例。对照组采用常规治疗,如一般护肝、降酶、退黄等治疗。治疗组在对照组治疗的基础上采用拉米夫定片(100mg/片)3～100mg.kg-1.d-1口服。观察2组患儿治疗后12、24、52个月HBV DNA阴转、HBeAg阴转、ALT复常及临床疗效、不良反应等情况。结果治疗组总有效率明显高于对照组(P<0.05)。治疗组患儿治疗后24、52个月HBV DNA、HBeAg阴转率及ALT复常率均明显高于对照组(均P<0.01)。2组患儿均未发生不良反应。结论拉米夫定治疗儿童慢性乙型肝炎有较好的疗效,是治疗儿童慢性乙型肝炎较理想的药物。
Objective To explore the efficacy and safety of lamivudine tablets in children with chronic hepatitis B.Methods A total of 218 children with chronic hepatitis B were divided into two groups.Control group（n=102） was given conventional therapy,such as hepatoprotection,enzyme reduction and jaundice elimination.Treatment group（n=116） was given conventional therapy in combination with oral lamivudine tablets（100 mg/piece,3~100 mg·kg-1·d-1）.HBV-DNA conversion,HBeAg conversion,alanine aminotransferase（ALT） normalization,curative effects and adverse reactions were observed at 12,24 and 52 months after treatment.Results The total effective rate in treatment group was significantly higher than that in control group（P0.05）.Furthermore,lamivudine therapy significantly increased HBV DNA negative rate,HBeAg negative rate and ALT normalization rate at 24 and 52 months after treatment,compared with conventional therapy（all P0.01）.No adverse reactions occurred in all patients.Conclusion Lamivudine,as an ideal drug,is effective in children with chronic hepatitis B.
出处
《实用临床医学（江西）》
CAS
2012年第1期16-18,共3页
Practical Clinical Medicine
